EDASA Scientific Raises Funds for 5-Year Drug Discovery Program

EDASA Scientific LTD, a Medicinal Chemistry CRO is pleased to announce that in a joint effort with an American-based biotech, they successfully managed to raise government funds for a five-year drug discovery research program in the antiviral field. EDASA Scientific will not retain any IP and will act solely as a service organization.

EDASA Scientific is playing a crucial role in the project with the medicinal chemistry optimization of the current active new chemical entity into an ideal compound candidate for clinical development.

Dr Altieri, EDASA Scientific Bus. Dev. Director said: "This represents a remarkable milestone for EDASA Scientific, which will ultimately position the company as a specialist in the Viral Drug Discovery Area, as well as be a reliable partner for Led Optimization Projects. Moreover, it demonstrates the efficiency of our flexible business model and our real capability to raise funding for joint projects from our clients and collaborators. Having the program funded for five years certainly contributes to company growth and stability, as well as EDASA Scientific's capabilities in the Medicinal Chemistry CRO Market."

ABOUT EDASA Scientific Limited: EDASA Scientific Limited is a Chemistry Contract Research Organization active in Organic Synthetic Chemistry. Exclusive access to the best Russian brains and facilities. Cutting-edge thinking. Progressive research. A highly experienced and flexible approach. EDASA delivers innovative compounds and creative solutions with considerable economies of cost and time.

CONTACT: Andrea Altieri Director of Business Development [email protected] Tel. +7 (903) 127-47-96

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.